Close Menu

NEW YORK – Tempus said on Wednesday that it will collaborate with A2 Biotherapeutics to develop a companion diagnostic test for A2's loss of heterozygosity-targeted cell therapy platform, Tmod.

According to Tempus, the partnership could also expand in the future to include development of additional CDx tests for A2’s other clinical development programs.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 


As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.